Glenmark has agreed to a $29.6 million settlement to resolve allegations that it participated in a scheme to inflate prices of generic medications across the US. The settlement covers claims from 48 states and territories accusing the company of anticompetitive conduct between May 2009 and December 2019.
Details of the Allegations and Settlement
The lawsuit alleged that Glenmark collaborated with other pharmaceutical manufacturers through executive meetings and communications to coordinate price fixing and restrict competition in the generic drug market. The companies involved are said to have kept generic medication prices artificially high, affecting consumers nationwide.
The settlement funds are designated for consumer restitution, aimed at reimbursing patients who were overcharged for qualifying generic drugs during the decade-long period. Once the claims process opens, eligible individuals who purchased Glenmark’s generics or those from previously settled companies can submit claims via the official site aggenericdrugs.com.
Distribution and Impact
States expected to receive the largest portions of the payout include California, Texas, New York, Florida, Pennsylvania, Illinois, Ohio, Michigan, Georgia, and North Carolina. This settlement marks a significant move to address systematic antitrust violations in the pharmaceutical industry that have affected prescription drug costs for consumers.
This information is provided for informational purposes only and does not constitute financial advice.
